TABLE 1.
Correlation of clinical characteristics of primary GCT to the recurrence status
| Parameter | Variable | n (%) | P | |
|---|---|---|---|---|
| Nonrecurrent (n = 113)* | Recurrent (n = 12) | |||
| Age at diagnosis | ≤50 | 64 (59.3) | 4 (33.3) | 0.47 |
| > 50 | 44 (40.7) | 8 (66.7) | ||
| Race | White | 12 (16.7) | 8 (66.7) | 0.001 |
| Black | 46 (63.9) | 3 (25.0) | ||
| Other | 14 (19.4) | 1 (8.3) | ||
| BMI (median) | 31.5 | 27.7 | 0.41 | |
| Stage | Stage I-II | 111 (98.2) | 8 (66.7) | 0.001 |
| Stage III-IV | 2(1.8) | 4 (33.3) | ||
| Lymph node status | Negative | 28 (93.3) | 5 (100.0) | 1.0 |
| Positive | 2 (6.7) | 0 (0.0) | ||
| Lymphadenectomy | Yes | 30 (27.3) | 4 (66.7) | 0.66 |
| No | 80 (72.7) | 2 (33.3) | ||
| Treatment | Surgery only | 63 (92.6) | 2 (16.7) | 0.0001 |
| Surgery+chemo | 3 (4.4) | 10 (83.3) | ||
| Chemotherapy | 2 (2.9) | 0 (0.0) | ||
| Type of surgery | USO | 27 (40.9) | 4 (33.3) | 0.54 |
| BSO | 7 (10.6) | 1 (8.3) | ||
| TAH/USO | 26 (39.4) | 7 (58.3) | ||
| TAH/BSO | 6 (9.1) | 0 (0.0) | ||
| Median survival (mo) | 138 | 83 | 0.94 | |
| DFI (mo) | 135 | 60 | 0.12 | |
| Vital status | Alive | 77 (68.1) | 6 (50.0) | 0.21 |
| Dead | 36 (31.9) | 6 (50.0) | ||
*
Data is missing in some cases.
Bold values are statistically significant.
BMI indicates body mass index; DFI, disease-free interval; GCT, granulosa cell tumors.